UI Hospitals and Clinics
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
Participants in this study have been diagnosed with multiple myeloma and have not yet been treated. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. The purpose of this study is to determine if elotuzumab given with lenalidomide and dexamethasone is more effective in the initial treatment of multiple myeloma compared with a standard treatment of lenalidomide and dexamethasone alone. This study will also assess the safety of the combination of drugs along with how well the participant's body will process elotuzumab. Treatment will continue until the disease gets worse, or there are unacceptable side effect, or participant or their doctor decides it is not in their best interest to participate any longer.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.